Navigation Links
Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
Date:10/22/2008


- Worldwide Net Revenue Increased 4% for the 2008 Third Quarter and

5% for the 2008 First Nine Months

- Third Quarter Revenue Growth in Pharmaceuticals Division Led by

Solid Growth of Enbrel +32%, Nutritionals +18% and Prevnar +13%

- Guidance for 2008 Full Year Diluted EPS, before Certain Significant

Items, Revised to a Range of $3.49 to $3.55

- Dividend to Stockholders Increased by 7.1%

MADISON, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today reported results for the 2008 third quarter and first nine months ending September 30, 2008. Worldwide net revenue increased 4%, to $5.8 billion, for the 2008 third quarter and 5%, to $17.5 billion, for the first nine months of 2008. Excluding the favorable impact of foreign exchange, worldwide net revenue increased 2% for the 2008 third quarter and increased 1% for the 2008 first nine months.

"Wyeth's results so far this year reflect the continued solid performance of our major growth engines - Enbrel, Prevnar and our Nutritionals franchise," said Bernard Poussot, Chairman, President and Chief Executive Officer. "For the first nine months of 2008, our revenues grew five percent despite the launch of Protonix generics last December. Wyeth has become a well diversified global biopharmaceutical company with 43 percent of its revenues represented by vaccines, biotechnology and nutritional products."

Product Highlights for the Third Quarter and First Nine Months of 2008

The following table presents worldwide net revenue from Wyeth's principal products for the 2008 third quarter and first nine months, together with the percentage changes from the comparable periods in th
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
2. Wyeth Announces Increase in Common Stock Dividend
3. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
4. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
5. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
6. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
7. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
8. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
9. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
10. Wyeth Declares Common and Preferred Stock Dividends
11. Wyeth Pharmaceuticals Announces Organizational Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... RURO, Inc., a leading LIMS, RFID ... the latest major content upgrade to its bestselling, Commercial ... Upgrade is a significant advancement of FreezerPro® system ... experience, while also simplifying , New ... Download available immediately for free to “Gold” ...
(Date:5/5/2015)... 2015  Blueprint Medicines (NASDAQ: BPMC ) ... offering of 9,367,708 shares of common stock at ... including shares of common stock issued upon the ... to purchase additional shares. The gross proceeds from ... approximately $168.6 million, before underwriting discounts and estimated offering ...
(Date:5/5/2015)... May 5, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... results for the three months ended March 31, 2015 ... amounts are in Canadian dollars. Effective ... end from May 31 to December 31. As a ... reported is for the three months ended March 31, ...
(Date:5/5/2015)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular diagnostics ... of foodborne pathogens,  today announced that Paul G. Thomas ... 2015 Health Care Conference on May 12 at 8:00am PT. ... Las Vegas NV. ... the investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:RURO Releases version 7 of FreezerPro® software 2Blueprint Medicines Announces Closing of Initial Public Offering 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8
... ROCKVILLE, Md., Feb. 11 OriGene Technologies, Inc. ... $6.5 million in a private equity financing. With ... assets of privately held Shenzhen P&A Biotech, a ... the research community. With this acquisition OriGene completes ...
... N.Y., Feb. 11 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... and Mr. Boaz Shweiger have been appointed to XTL,s ... will also be assuming,the role of Co-Chief Executive Officer, ... strategic alternatives. , Ron Bentsur, ...
... Ferring Research Institute Introduce New Research Base and ... DiegoSAN DIEGO, Feb. 11 Leading global biopharmaceutical ... Institute have opened a new and expanded, 38,000-square-foot ... will be dedicated to further development of peptide ...
Cached Biology Technology:OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 3Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 2Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 3Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 4
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/27/2015)... April 27, 2015  For more than four decades, ... has been the premier worldwide event for the unmanned ... a must-attend event for any local, national, or trade ... emerging commercial markets and current applications of unmanned technologies. ... this projected $48 billion industry, and how it will ...
(Date:4/27/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... the first week of May, 2015 and will be ... Gino Pereira , Chief Executive ... company as Wocket® enters the consumer market. We would ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... 2013 Dr. Jeffrey Trent, President and Research Director ... state-of-the-art genomics research July 16 at the Brookings Institution. ... Director of the National Human Genome Research Institute, is ... 2nd annual State of Biomedical Innovation Conference, which will ...
... At the end of the last Ice Age, as the ... Ocean came to life. During a brief pulse of biological ... with phytoplankton, amoeba-like foraminifera and other tiny creatures, who thrived ... beganjust a few hundred years later. Researchers have ...
... may prevent key grassland species from taking hold and ... has shown., Work by scientists at Newcastle University, UK, ... biodiversity and how this might inform future restoration work., ... gardener,s prize petunias or strawberry patch, still relatively little ...
Cached Biology News:TGen President Dr. Jeffrey Trent speaks at Brookings Institution biomedical conference 2Scientists solve a 14,000-year-old ocean mystery 2Scientists solve a 14,000-year-old ocean mystery 3Grazing slugs hinder grassland restoration 2
...
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
... membrane filters suitable for use in the Microsart ... of each filter, in a specially designed individual ... pleating of the band of membrane filter units ... The shape of the sealed band guarantees uniform ...
... The model 55S Rocking Shaker provides ... and blotted membranes. The very slow ... degree of tilt provide a gentle ... over gels and blotted membranes to ...
Biology Products: